/
AUPH
$16.97+$0.18 (+1.07%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.2B
129M shares
52-week range
$7.29 – $19.25
81% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.38%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$4.00
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $463.0K | $318.0K | $50.1M | $45.6M | $134.0M | $175.5M | $235.1M | $283.1M |
| Cost of revenue | $41.4M | $0 | $0 | $1.1M | $5.7M | $14.1M | $28.2M | $32.7M |
| Gross profit | −$40.9M | $318.0K | $50.1M | $44.5M | $128.4M | $161.4M | $206.9M | $250.4M |
| Gross margin | -8837.8% | 100.0% | 100.0% | 97.6% | 95.8% | 91.9% | 88.0% | 88.5% |
| R&D | $41.4M | $52.9M | $50.3M | $51.1M | $45.0M | $49.6M | $20.8M | $32.5M |
| Operating income | −$56.2M | −$90.9M | −$104.3M | −$180.7M | −$111.5M | −$91.7M | −$4.7M | $104.9M |
| EBITDA | −$53.9M | −$89.8M | −$102.9M | −$177.4M | −$103.6M | −$63.0M | $31.7M | $127.8M |
| Net income | −$64.1M | −$88.4M | −$102.7M | −$181.0M | −$108.2M | −$78.0M | $5.8M | $287.2M |
| Net margin | -13848.8% | -27794.0% | -204.9% | -396.8% | -80.7% | -44.5% | 2.4% | 101.5% |
| EPS (diluted) | -0.76 | -1.33 | -0.87 | -1.40 | -0.76 | -0.54 | 0.04 | 2.07 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $326M | $0.96 | $0.76–$1.13 | 4 |
| 2027 | $388M | $1.24 | $0.78–$1.68 | 4 |
| 2028 | $473M | $1.80 | $0.59–$3.20 | 4 |
| 2029 | $494M | $1.71 | $1.59–$1.89 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
www.auriniapharma.com- Employees
- 128
- IPO / List date
- Oct 21, 2009
- HQ
- EDMONTON, A0
Held by traders on TradeandTell
No one on the platform currently holds AUPH.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,663,835 | $24.7M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AUPH yet.
